Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 4/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | GLP1R | P43220 | 2/20 | 0.52 |
| ▸ | GCGR | P47871 | 2/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 7/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | MC3R | P41968 | 1/20 | 0.49 |
| ▸ | MC1R | Q01726 | 1/20 | 0.49 |
| ▸ | F11 | P03951 | 1/20 | 0.49 |
| ▸ | RXFP4 | Q8TDU9 | 2/20 | 0.49 |
| ▸ | RXFP3 | Q9NSD7 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30883974 | 1.00 | KLK5 (0.55) | KLK5CHRNA7GLP1RGCGREPHA2 | |
| SCHEMBL23824134 | 0.81 | CHRNA7 (0.61) | KLK5CHRNA7 | |
| SCHEMBL23824135 | 0.76 | ACE2 (0.57) | KLK5EPHA2ACE2ACE | |
| SCHEMBL29511745 | 0.74 | INSR (0.61) | KLK5ACE2ACEMC4RMC3R | |
| SCHEMBL28586826 | 0.74 | RXFP4 (0.61) | KLK5GLP1RGCGRMC4RMC1R | |
| SCHEMBL29392338 | 0.74 | TSLP (0.57) | GLP1RGCGRMC4RMC3RF11 | |
| SCHEMBL29476611 | 0.74 | TSLP (0.54) | MC4RMC3RF11 | |
| SCHEMBL29482473 | 0.74 | F11 (0.56) | GLP1RGCGRF11 | |
| SCHEMBL29461365 | 0.74 | KLK5 (0.57) | KLK5GLP1RF11RXFP4RXFP3 | |
| SCHEMBL31332040 | 0.73 | SSTR2 (0.64) | GLP1RGCGRRXFP4RXFP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082486-A1 | SYNTHESIZED ANTI-CANCER LIPOPEPTIDE AND USE THEREOF | 永州中古生物技术有限公司 | 2025-04-24 | — | — | WO | claimed |
| CN-119841960-A | Synthetic anticancer lipopeptide and application thereof | 永州中古生物技术有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-118103340-A | Method for manufacturing medical injection device and medical injection device manufactured by same | 斯特瓦纳托集团有限公司 | 2024-05-28 | — | — | CN | claimed |
| US-20230266330-A1 | EXOSOMAL TUMOR BIOMARKERS AND COLLECTIONS THEREOF | CORNELL UNIVERSITY | 2023-08-24 | — | — | US | claimed |
| EP-4176266-A2 | EXOSOMAL TUMOR BIOMARKERS AND COLLECTIONS THEREOF | Cornell University (US) | 2023-05-10 | — | — | EP | claimed |
| EP-4713444-A2 | FUSION PROTEINS COMPRISING CAS ENZYMES AND DNA-BINDING PROTEINS | Sarepta Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250295587-A1 | COMPLEX LIPID NANOPARTICLES ENCAPSULATING POLYPEPTIDES AND USES THEREOF | SAIL BIOMEDICINES, INC. | 2025-09-25 | — | — | US | disclosed |
| US-12303547-B2 | Compound, use, pharmaceutical composition, method of diagnosis, method of treatment, and method of transportation and/or internalization of a compound into eukaryotic cells | INSTITUTO BUTANTAN (BR) | 2025-05-20 | — | — | US | disclosed |
| WO-2025082486-A1 | SYNTHESIZED ANTI-CANCER LIPOPEPTIDE AND USE THEREOF | 永州中古生物技术有限公司 | 2025-04-24 | — | — | WO | disclosed |
| WO-2025082486-A1 | SYNTHESIZED ANTI-CANCER LIPOPEPTIDE AND USE THEREOF | 永州中古生物技术有限公司 | 2025-04-24 | — | — | WO | disclosed |
| CN-119841960-A | Synthetic anticancer lipopeptide and application thereof | 永州中古生物技术有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20240408312-A1 | METHOD OF MANUFACTURING A MEDICAL INJECTION DEVICE AND MEDICAL INJECTION DEVICE THUS OBTAINED | STEVANTO GROUP S.P.A. (IT) | 2024-12-12 | — | — | US | disclosed |
| WO-2023052354-A1 | NPM1-DEPENDING LEUKEMIA AGENTS | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2023-04-06 | — | — | WO | disclosed |
| CN-115803337-A | Citrullinated nucleolar phosphoprotein peptides as cancer vaccines | 斯坎塞尔有限公司 | 2023-03-14 | — | — | CN | disclosed |
| EP-4139339-A1 | CITRULLINATED NUCLEOPHOSMIN PEPTIDES AS CANCER VACCINES | Scancell Limited (GB) | 2023-03-01 | — | — | EP | disclosed |
| US-11579140-B2 | Methods related to bronchial premalignant lesion severity and progression | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-02-14 | — | — | US | disclosed |
| WO-2022127945-A3 | CIGB-300 FOR USE IN THE THE INDUCTION OF ANTITUMOR AND ANTIVIRAL IMMUNTY | CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CU) | 2022-12-22 | — | — | WO | disclosed |
| US-20220288150-A1 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2022-09-15 | — | — | US | disclosed |
| US-20220152139-A1 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2022-05-19 | — | — | US | disclosed |
| US-20220088122-A1 | COMPOUND, USE, PHARMACEUTICAL COMPOSITION, METHOD OF DIAGNOSIS, METHOD OF TREATMENT, AND METHOD OF TRANSPORTATION AND/OR INTERNALIZATION OF A COMPOUND INTO EUKARYOTIC CELLS | INSTITUTO BUTANTAN (BR) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12303547-B2 | Compound, use, pharmaceutical composition, method of diagnosis, method of treatment, and method of transportation and/or internalization of a compound into eukaryotic cells | CANX, PHAX, EEA1 | KLK5 1451/4885CHRNA7 3338/4885GLP1R 1625/4885 |
| US-20220088122-A1 | COMPOUND, USE, PHARMACEUTICAL COMPOSITION, METHOD OF DIAGNOSIS, METHOD OF TREATMENT, AND METHOD OF TRANSPORTATION AND/OR INTERNALIZATION OF A COMPOUND INTO EUKARYOTIC CELLS | CANX, PHAX, EEA1 | KLK5 1451/4885CHRNA7 3338/4885GLP1R 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.